|  |
| --- |
| **Supplemental Table 2.** Characteristics of 4,807 patient ages ≤39 years with classical Hodgkin lymphoma, overall and by age group, California, 2007 - 2017. |
|  |  **<15 years** | **15 – 21 years** | **22 – 39 years** | **p-value\*** |
|  | N (%) | N (%) | N (%) |  |
|  | N= 405 (8) | N= 1,200 (25) | N= 3,202 (67) |  |
| **Race/ethnicity** |  |  |  |  |
|  White | 122 (30) | 567 (47) | 1609 (50) |  |
|  Black | 36 (9) | 74 (6) | 226 (7) |  |
|  Hispanic | 216 (53) | 412 (34) | 983 (31) |  |
|  Asian/PI | 29 (7) | 124 (10) | 327 (10) |  |
|  Other/Unknown | ~ | 23 (2) | 57 (2) | **<.0001** |
| **Sex** |  |  |  |  |
|  Male | 244 (60) | 564 (47) | 1666 (52) |  |
|  Female | 161 (40) | 636 (53) | 1536 (48) | **<.0001** |
| **Stage at diagnosis** |  |  |  |  |
|  Stage I | 35 (9) | 69 (6) | 316 (10) |  |
|  Stage II | 174 (43) | 605 (50) | 1561 (49) |  |
|  Stage III | 97 (24) | 240 (20) | 613 (19) |  |
|  Stage IV | 87 (21) | 222 (19) | 546 (17) |  |
|  Unknown | 12 (3) | 64 (5) | 166 (5) | **<.0001** |
| **Health insurance** |  |  |  |  |
|  Private | 208 (51) | 785 (65) | 2221 (69) |  |
|  Public/none | 188 (46) | 387 (32) | 871 (27) |  |
|  Unknown | 9 (2) | 28 (2) | 110 (3) | **<.0001** |
| **Neighborhood SES** |  |  |  |  |
|  Low SES | 171 (42) | 356 (30) | 940 (29) |  |
|  Middle SES | 132 (33) | 398 (33) | 1159 (36) |  |
|  High SES | 102 (25) | 446 (37) | 1103 (34) | **<.0001** |
| **B symptoms** |  |  |  |  |
|  No | 255 (63) | 559 (47) | 1451 (45) |  |
|  Yes | 132 (33) | 544 (45) | 1399 (44) |  |
|  Unknown | 18 (4) | 97 (8) | 352 (11) | **<.0001** |
| **Histology** |  |  |  |  |
|  Classical HL, NOS | 86 (21) | 282 (24) | 768 (24) |  |
|  Mixed cellularity | 69 (17) | 67 (6) | 270 (8) |  |
|  Nodular sclerosis | 250 (62) | 851 (71) | 2164 (68) | **<.0001** |
| **NCI Cancer Center** |  |  |  |  |
|  No | 193 (48) | 798 (67) | 2514 (79) |  |
|  Yes | 212 (52) | 402 (34) | 688 (21) | **<.0001** |
| **Chemotherapy regimen** |  |  |  |  |
|  ABVD | 56 (14) | 609 (51) | 2248 (70) |  |
|  ABVEPC | 65 (16) | 93 (8) | ~ |  |
|  BEACOPP | 25 (6) | 43 (4) | 30 (1) |  |
|  Stanford | 31 (8) | 65 (5) | 138 (4) |  |
|  Modified regimens | 166 (41) | 217 (18) | 278 (9) |  |
|  Other standard regimen | 46 (11) | 51 (4) | 63 (2) |  |
|  Unknown chemotherapy  | 12 (3) | 89 (7) | 319 (10) | **<.0001** |
| **Radiation therapy** |  |  |  |  |
|  No radiation/unknown | 230 (57) | 753 (63) | 2358 (74) |  |
|  Radiation | 175 (43) | 447 (37) | 844 (26) | **<.0001** |
| **Hematopoietic cell transplantation** |  |  |  |  |
|  Yes | 12 (3) | 116 (10) | 332 (10) |  |
|  No | 393 (97) | 1084 (90) | 2870 (90) | **<.0001** |
| **Cause of death** |  |  |  |  |
|  Alive | 397 (98) | 1146 (96) | 3023 (94) |  |
|  Death from lymphoma (HL+NHL) | ~ | 25 (3) | 125(4) |  |
|  Death from other cancer | ~ | ~ | ~ |  |
|  Death from heart/cerebrovascular | ~ | ~ | 5 (<1) |  |
|  Death from other cause | ~ | 7 (1) | 35 (<1) |  |
|  Death from unknown cause | 3 (1) | ~ | 13 (<1) | 0.0729 |
| Abbreviations: NH: non-Hispanic; SES: socioeconomic status; NOS: not-otherwise specified; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine ABVE-PC: doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone Stanford V: doxorubicin, vinblastine, nitrogen mustard, etoposide, vincristine, bleomycin, prednisone CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone  |
| \*Chi-squared tests were used to assess patient, clinical, and treating facility characteristics associated with age. ~Data not shown due to too few (<5) events |